BIXT Stock Overview
Bioxytran, Inc., a clinical stage pharmaceutical company, focuses on the development, manufacture, and commercialization of therapeutic drugs to address hypoxia in humans.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Bioxytran, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.13 |
| 52 Week High | US$0.54 |
| 52 Week Low | US$0.071 |
| Beta | -0.76 |
| 1 Month Change | 18.87% |
| 3 Month Change | -0.32% |
| 1 Year Change | -72.73% |
| 3 Year Change | -23.01% |
| 5 Year Change | -88.10% |
| Change since IPO | -56.37% |
Recent News & Updates
Recent updates
Shareholder Returns
| BIXT | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 6.4% | 1.0% | 1.2% |
| 1Y | -72.7% | 0.7% | 24.9% |
Price Volatility
| BIXT volatility | |
|---|---|
| BIXT Average Weekly Movement | 15.2% |
| Biotechs Industry Average Movement | 11.6% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: BIXT has not had significant price volatility in the past 3 months.
Volatility Over Time: BIXT's weekly volatility (15%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2008 | 3 | David Platt | www.bioxytraninc.com |
Bioxytran, Inc., a clinical stage pharmaceutical company, focuses on the development, manufacture, and commercialization of therapeutic drugs to address hypoxia in humans. The company’s lead drug candidate is BXT-25, an oxygen-carrying small molecule consisting of bovine hemoglobin stabilized with a co-polymer for use in the treatment of hypoxic conditions in the brain resulting from stroke, and hypoxic conditions in wounds to prevent necrosis and to promote healing. It is also developing ProLectin-Rx, a polysaccharide derived from pectin that binds to, and blocks the activity of galectin-1, a type of galectin for treatment of mild to moderate cases of Covid-19.
Bioxytran, Inc. Fundamentals Summary
| BIXT fundamental statistics | |
|---|---|
| Market cap | US$25.54m |
| Earnings (TTM) | -US$4.30m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-5.3x
P/E RatioIs BIXT overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BIXT income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$4.30m |
| Earnings | -US$4.30m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.025 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | -101.2% |
How did BIXT perform over the long term?
See historical performance and comparison